nodular lymphocyte predominant Hodgkin lymphoma

Summary

nodular lymphocyte predominant Hodgkin lymphoma (MONDO:0044778) is a cancer and 4 clinical trials. Top therapeutic interventions include rituximab. A subtype of Hodgkins lymphoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Prevalence: Unknown (Worldwide) [Orphanet-validated]
• Phenotypes (HPO): 14
• Clinical trials: 4

Clinical features

Epidemiology

Prevalence records

22 prevalence record(s), Orphanet, top 20 (validated / broadest geography first):

Type	Class	Value	Geography	Validation
Annual incidence	1-9 / 1 000 000	0.12	Worldwide	Validated
Annual incidence	<1 / 1 000 000	0.095	Europe	Validated
Annual incidence	<1 / 1 000 000	0.041	Austria	Validated
Annual incidence	<1 / 1 000 000	0.006	Bulgaria	Validated
Annual incidence	<1 / 1 000 000	0.099	Czech Republic	Validated
Annual incidence	<1 / 1 000 000	0.037	Estonia	Validated
Annual incidence	<1 / 1 000 000	0.097	Germany	Validated
Annual incidence	<1 / 1 000 000	0.074	Ireland	Validated
Annual incidence	<1 / 1 000 000	0.038	Latvia	Validated
Annual incidence	<1 / 1 000 000	0.008	Lithuania	Validated
Annual incidence	<1 / 1 000 000	0.013	Poland	Validated
Annual incidence	<1 / 1 000 000	0.055	Portugal	Validated
Annual incidence	<1 / 1 000 000	0.053	Slovakia	Validated
Annual incidence	<1 / 1 000 000	0.056	Slovenia	Validated
Annual incidence	<1 / 1 000 000	0.092	United Kingdom	Validated
Annual incidence	1-9 / 1 000 000	0.128	Belgium	Validated
Annual incidence	1-9 / 1 000 000	0.285	Finland	Validated
Annual incidence	1-9 / 1 000 000	0.124	Italy	Validated
Annual incidence	1-9 / 1 000 000	0.226	Norway	Validated
Annual incidence	1-9 / 1 000 000	0.14	Spain	Validated

Signs & symptoms

Clinical features (HPO)

14 HPO clinical features (Orphanet curated; top 14 by frequency):

HPO ID	Term	Frequency
HP:0002665	Lymphoma	Very frequent (80-99%)
HP:0002716	Lymphadenopathy	Very frequent (80-99%)
HP:0002721	Immunodeficiency	Very frequent (80-99%)
HP:0001945	Fever	Frequent (30-79%)
HP:0000975	Hyperhidrosis	Occasional (5-29%)
HP:0000989	Pruritus	Occasional (5-29%)
HP:0001744	Splenomegaly	Occasional (5-29%)
HP:0001824	Weight loss	Occasional (5-29%)
HP:0002039	Anorexia	Occasional (5-29%)
HP:0002240	Hepatomegaly	Occasional (5-29%)
HP:0003002	Breast carcinoma	Occasional (5-29%)
HP:0005561	Abnormality of bone marrow cell morphology	Occasional (5-29%)
HP:0012191	B-cell lymphoma	Occasional (5-29%)
HP:0012378	Fatigue	Occasional (5-29%)

Identifiers

Disease identifiers

Field	Value
Canonical name	nodular lymphocyte predominant Hodgkin lymphoma
Mondo ID	MONDO:0044778
Orphanet	86893
ICD-10-CM	C81.0
ICD-11	331115338
NCIT	C7258
UMLS	C1334968
MedGen	233758
GARD	0019079
Is cancer (heuristic)	yes

Also known as: Hodgkin lymphoma nodular LP, NOS · Hodgkin lymphoma nodular lymphocyte predominant type, NOS · NLPHL · nodular lymphocyte predominant Hodgkin lymphoma · nodular lymphocyte predominant Hodgkin’s lymphoma · nodular lymphocyte-predominant Hodgkin lymphoma

Data availability: 1 cell line.

Disease family

This is a subtype of Hodgkins lymphoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › hematopoietic and lymphoid system neoplasm › hematopoietic and lymphoid cell neoplasm › lymphoid neoplasm › lymphoma › Hodgkins lymphoma › nodular lymphocyte predominant Hodgkin lymphoma

Related subtypes (4): splenic hodgkin lymphoma, classic Hodgkin lymphoma, lymphoma, Hodgkin, X-linked pseudoautosomal, lymphoma, Hodgkin, Y-linked pseudoautosomal

Subtypes (1): adult nodular lymphocyte predominant Hodgkin lymphoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 4.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	2
Not specified	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00003820	PHASE2	COMPLETED	Rituximab in Treating Patients With Hodgkin’s Lymphoma
NCT02626884	PHASE2	COMPLETED	Ibrutinib in Relapsed Nodular Lymphocyte-predominant Hodgkin Lymphoma (NLPHL)
NCT06098430	Not specified	RECRUITING	Patient-Reported Outcomes and Quality of Life in Adult and Pediatric Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)
NCT04858568	Not specified	COMPLETED	Immune Responses to COVID-19 Vaccination in Lymphoma Patients

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
RITUXIMAB	4	1